Infinity Pharmaceuticals (INFI) to Release Earnings on Monday

Infinity Pharmaceuticals (NASDAQ:INFIGet Rating) is scheduled to be posting its quarterly earnings results before the market opens on Monday, November 14th. Analysts expect Infinity Pharmaceuticals to post earnings of ($0.05) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Infinity Pharmaceuticals (NASDAQ:INFIGet Rating) last posted its earnings results on Tuesday, August 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. Infinity Pharmaceuticals had a negative return on equity of 299.00% and a negative net margin of 2,110.33%. The company had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.68 million. On average, analysts expect Infinity Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Infinity Pharmaceuticals Stock Performance

INFI stock opened at $1.19 on Friday. Infinity Pharmaceuticals has a fifty-two week low of $0.46 and a fifty-two week high of $2.81. The business’s 50-day moving average is $1.23 and its two-hundred day moving average is $0.97. The company has a market cap of $106.24 million, a price-to-earnings ratio of -2.29 and a beta of 1.40.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its stake in shares of Infinity Pharmaceuticals by 9.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 235,240 shares of the biotechnology company’s stock worth $269,000 after buying an additional 19,790 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Infinity Pharmaceuticals by 12.8% during the second quarter. Goldman Sachs Group Inc. now owns 232,460 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 26,345 shares in the last quarter. Mirabella Financial Services LLP purchased a new stake in shares of Infinity Pharmaceuticals during the first quarter worth about $34,000. State Street Corp grew its position in shares of Infinity Pharmaceuticals by 4.8% during the first quarter. State Street Corp now owns 1,884,979 shares of the biotechnology company’s stock worth $2,149,000 after purchasing an additional 86,006 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Infinity Pharmaceuticals by 161.3% during the first quarter. Renaissance Technologies LLC now owns 957,460 shares of the biotechnology company’s stock worth $1,092,000 after purchasing an additional 591,065 shares in the last quarter. Institutional investors own 33.81% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Infinity Pharmaceuticals in a report on Wednesday, October 12th. They issued a “hold” rating on the stock.

Infinity Pharmaceuticals Company Profile

(Get Rating)

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors.

Read More

Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.